Prognostic value of perfusion MR imaging of high-grade astrocytomas: Long-term follow-up study

American Journal of Neuroradiology

Volumn 29, Issue 8, 2008, Pages 1505-1510

  Hirai, Toshinori ^a   Murakami, R ^a   Nakamura, H ^a   Kitajima, M ^a   Fukuoka, H ^a   Sasao, A ^a   Akter, M ^a   Hayashida, Y ^a   Toya, R ^a   Oya, N ^a   Awai, K ^a   Iyama, K ^a   Kuratsu, J I ^a   Yamashita, Y ^a  

^a KUMAMOTO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; ASTROCYTOMA; BIOPSY; BRAIN BLOOD VOLUME; BRAIN FUNCTION; CLINICAL ARTICLE; FEMALE; FOLLOW UP; GLIOBLASTOMA; HAZARD RATIO; HUMAN; HUMAN TISSUE; MALE; MENTAL HEALTH; NUCLEAR MAGNETIC RESONANCE IMAGING; PROGNOSIS; RATING SCALE; SURVIVAL RATE; SYMPTOMATOLOGY;

ADULT; AGED; ASTROCYTOMA; BRAIN NEOPLASMS; FEMALE; FOLLOW-UP STUDIES; HUMANS; JAPAN; LONGITUDINAL STUDIES; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; PREVALENCE; PROGNOSIS; SURVIVAL ANALYSIS; SURVIVAL RATE;

EID: 51649087170     PISSN: 01956108     EISSN: None     Source Type: Journal    
DOI: 10.3174/ajnr.A1121     Document Type: Article

References (34)

1. Louis DN, Ohgaki H, Wiestler OD, et al. World Health Organization Classification of Tumours of the Central Nervous System: Astrocytic Tumours. Lyon, France: IARC Press; 2007:13-52
2. Gupta T, Sarin R. Poor-prognosis high-grade gliomas: evolving an evidence-based standard of care. Lancet Oncol 2002;3:557-64
3. Behin A, Hoang-Xuan K, Carpentier AF, et al. Primary brain tumours in adults. Lancet 2003;361:323-31
4. Stewart LA. Chemotherapy in adult high-grade glioma: a systematic review and meta-analysis of individual patient data from 12 randomised trials. Lancet 2002;359:1011-18
5. Scott CB, Scarantino C, Urtasun R, et al. Validation and predictive power of Radiation Therapy Oncology Group (RTOG) recursive partitioning analysis classes for malignant glioma patients: a report using RTOG 90-06. Int J Radiat Oncol Biol Phys 1998;40:51-55
6. Jackson RJ, Fuller GN, Abi-Said D, et al. Limitations of stereotactic biopsy in the initial management of gliomas. Neuro Oncol 2001;3:193-200
7. Gilles FH, Brown WD, Leviton A, et al. Limitations of the World Health Organization classification of childhood supratentorial astrocytic tumors: Children Brain Tumor Consortium. Cancer 2000;88:1477-83
8. Coons SW, Johnson PC, Scheithauer BW, et al. Improving diagnostic accuracy and interobserver concordance in the classification and grading of primary gliomas. Cancer 1997;79:1381-93
9. Aldape K, Simmons ML, Davis RL, et al. Discrepancies in diagnoses of neuroepithelial neoplasms: the San Francisco Bay Area Adult Glioma Study. Cancer 2000;88:2342-49
10. Aronen HJ, Gazit IE, Louis DN, et al. Cerebral blood volume maps of gliomas: comparison with tumor grade and histologic findings. Radiology 1994;191:41-51
11. Sugahara T, Korogi Y, Kochi M, et al. Correlation of MR imaging-determined cerebral blood volume maps with histologic and angiographic determination of vascularity in gliomas. AJR Am J Roentgenol 1998;171:1479-86
12. Knopp EA, Cha S, Johnson G, et al. Glial neoplasms: dynamic contrast-enhanced T2*-weighted MR imaging. Radiology 1999;211:791-98
13. Wong JC, Provenzale JM, Petrella JR, et al. Perfusion MR imaging of brain neoplasms. AJR Am J Roentgenol 2000;174:1147-57
14. Cha S, Johnson G, Wadghiri YZ, et al. Dynamic, contrast-enhanced perfusion MRI in mouse gliomas: correlation with histopathology. Magn Reson Med 2003;49:848-55
15. Leon SP, Folkerth RD, Black PM. Microvessel density is a prognostic indicator for patients with astroglial brain tumors. Cancer 1996;77:362-72
16. Lev MH, Ozsunar Y, Henson JW, et al. Glial tumor grading and outcome prediction using dynamic spin-echo MR susceptibility mapping compared with conventional contrast-enhanced MR: confounding effect of elevated rCBV of oligodendrogliomas. AJNR Am J Neuroradiol 2004;25:214-21
17. Tzika AA, Astrakas LG, Zarifi MK, et al. Spectroscopic and perfusion magnetic resonance imaging predictors of progression in pediatric brain tumors. Cancer 2004;100:1246-56
18. Law M, Oh S, Babb JS, et al. Low-grade gliomas: dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging-prediction of patient clinical response. Radiology 2006;238:658-67
19. Oh J, Henry RG, Pirzkall A, et al. Survival analysis in patients with glioblastoma multiforme: predictive value of choline-to-N-acetylaspartate index, apparent diffusion coefficient, and relative cerebral blood volume. J Magn Reson Imaging 2004;19:546-54
20. Mills SJ, Patankar TA, Haroon HA, et al. Do cerebral blood volume and contrast transfer coefficient predict prognosis in human glioma? AJNR Am J Neuroradiol 2006;27:853-58
21. Rosen BR, Belliveau JW, Vevea JM, et al. Perfusion imaging with NMR contrast agents. Magn Reson Med 1990;14:249-65
22. Rosen BR, Belliveau JW, Buchbinder BR, et al. Contrast agents and cerebral hemodynamics. Magn Reson Med 1991;19:285-92
23. Wetzel SG, Cha S, Johnson G, et al. Relative cerebral blood volume measurements in intracranial mass lesions: interobserver and intraobserver reproducibility study. Radiology 2002;224:797-803
24. Watanabe K, Sato K, Biernat W, et al. Incidence and timing of p53 mutations during astrocytoma progression in patients with multiple biopsies. Clin Cancer Res 1997;3:523-30
25. Kowalczuk A, Macdonald RL, Amidei C, et al. Quantitative imaging study of extent of surgical resection and prognosis of malignant astrocytomas. Neurosurgery 1997;41:1028-36
26. Lacroix M, Abi-Said D, Fourney DR, et al. A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival. J Neurosurg 2001;95:190-98
27. Laws ER, Parney IF, Huang W, et al. Survival following surgery and prognostic factors for recently diagnosed malignant glioma: data from the Glioma Outcomes Project. J Neurosurg 2003;99:467-73
28. Sant M, van der Sanden G, Capocaccia R. Survival rates for primary malignant brain tumours in Europe. Eur J Cancer 1998;34:2241-47
29. Shinojima N, Kochi M, Hamada J, et al. The influence of sex and the presence of giant cells on postoperative long-term survival in adult patients with supratentorial glioblastoma multiforme. J Neurosurg 2004;101:219-26
30. Magrini SM, Ricardi U, Santoni R, et al. Patterns of practice and survival in a retrospective analysis of 1722 adult astrocytoma patients treated between 1985 and 2001 in 12 Italian radiation oncology centers. Int J Radiat Oncol Biol Phys 2006;65:788-99
31. Plunkett RJ, Lis A, Barone TA, et al. Hormonal effects on glioblastoma multiforme in the nude rat model. J Neurosurg 1999;90:1072-77
32. Seki Y, Suico MA, Uto A, et al. The ETS transcription factor MEF is a candidate tumor suppressor gene on the X chromosome. Cancer Res 2002;62:6579-86
33. Polin RS, Marko NF, Ammerman MD, et al. Functional outcomes and survival in patients with high-grade gliomas in dominant and nondominant hemispheres. J Neurosurg 2005;102:276-83
34. Provenzale JM, Mukundan S, Barboriak DP. Diffusion-weighted and perfusion MR imaging for brain tumor characterization and assessment of treatment response. Radiology 2006;239:632-49